MedTrace Logo

A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia

NCT02886494 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-10-13

Study results available
· View outcomes & findings →

Summary

A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient with Alzheimer's Disease or Vascular Dementia

Conditions

  • Alzheimer's Disease or Vascular Dementia

Interventions

DRUG

BAC treatment

BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks

DRUG

Matched vehicle

BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks

Sponsors & Collaborators

  • Charsire Biotechnology Corp.

    lead INDUSTRY

Principal Investigators

  • Stephen Thein · Pacific Research Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-11-01
Completion
2018-11-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02886494 on ClinicalTrials.gov